Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on May 2, 2016. The report details unregistered sales of equity securities pursuant to Item 3.02.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions.
Material Changes
The Company executed exchanges of Class B Common Stock and nonvoting common units of vTv Therapeutics LLC ("vTv Units") for Class A Common Stock on three dates:
- March 4, 2016: Issued 28,451 shares of Class A Common Stock.
- March 24, 2016: Issued 46,174 shares of Class A Common Stock.
- May 2, 2016: Issued 279,298 shares of Class A Common Stock.
In total, 353,923 shares of Class A Common Stock were issued in exchange for 353,923 shares of Class B Common Stock and 353,923 vTv Units. These issuances relied on the Section 4(a)(2) exemption from registration under the Securities Act of 1933.
Outlook and Contingencies
Under the terms of the Exchange Agreement, 23,183,943 shares of Class B Common Stock (and corresponding vTv Units) remain eligible for exchange. Holders may exchange these for Class A Common Stock on a one-for-one basis or for cash at the Company's option, subject to customary adjustments for stock splits or dividends.
Investor Verification Checklist
- Verify the total number of Class A shares outstanding following the May 2, 2016 issuance.
- Confirm the current market price of Class A Common Stock to assess the potential cash value of the remaining 23,183,943 exchangeable Class B shares.
- Review the Exchange Agreement for specific terms regarding the Company's option to pay cash versus issuing stock for future exchanges.